KRYS · Krystal Biotech, Inc.

Summary

Krystal Biotech, Inc. announced financial results for Q4 and full year 2025, reporting $107.1 million in Q4 VYJUVEK net product revenue and $389.1 million for the full year, with net income of $51.4 million ($1.70 diluted EPS) for Q4 and $204.8 million ($6.84 diluted EPS) for the year, alongside $955.9 million in cash and investments. The company provided pipeline updates including FDA RMAT for KB707 and Fast Track for KB111, plus FY2026 non-GAAP R&D and SG&A guidance of $175.0-$195.0 million.

Key takeaways

• Event Type: Earnings Release (Items: 2.02)